Table 2.

Efficacy in the intention-to-treat population

Variable	FOLFOX plus bevacizumab (n=177)	FOLFOXIRI plus bevacizumab (n=172)	HR or OR (95% CI)	P value
Progression-free survival
Events	129 (72.9%)	112 (65.1%)	0.64 (0.49 to 0.82)	0.0006
Median (95% CI), months	9.3 (8.5 to 10.7)	12.4 (11.1 to 14.0)
Response
Complete response	1 (0.6%)	4 (2.3%)
Partial response	91 (51.4%)	98 (57.0%)
Stable disease	64 (36.2%)	40 (23.3%)
Progressive disease	4 (2.3%)	6 (3.5%)
Not evaluable	17 (9.6%)	24 (14.0%)
Overall response rate	92 (52.0%)	102 (59.3%)	0.74 (0.49 to 1.13)	0.1685
95% CI	44.4 to 59.5	51.6 to 66.7
Duration of response
Median, months	8.1	9.9	0.56 (0.40 to 0.79)	0.0010
R0 resection	14 (7.9%)	12 (7.0%)	–	0.7400
95% CI	4.4 to 12.9	3.7 to 11.9
Overall survival
Events	149 (84.2%)	136 (79.1%)	0.84 (0.66 to 1.06)	0.1411
Median (95% CI), months	17.6 (15.1 to 21.2)	22.3 (17.8 to 26.4)

Data are n (%) unless otherwise stated.

Ratios listed are HRs, except for overall response rate for which an OR is presented.

FOLFOX, 5-fluorouracil, leucovorin and oxaliplatin; FOLFOXIRI, 5-fluorouracil, leucovorin, oxaliplatin and irinotecan.